ArticleBiochemical genetics2026
Exploration Biomarkers for Recurrence of Hepatocellular Carcinoma After Liver Transplantation Based on Bioinformatics Analysis.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction and validation of a prediction model for graft failure in pediatric liver transplant recipients based on the APRI-ALBI score: a retrospective study of 289 cases.Annals of medicine · 2026Article
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to explore thrombin-related prognostic biomarkers for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT). Bioinformatics analyses were conducted using TCGA-LIHC and GEO datasets. LASSO Cox regression screened thrombin-related genes (TRGs). Differential expression analysis, GSEA, and protein-protein interaction (PPI) network analysis were performed to identify key pathways and hub genes. Clinical validation included immunohistochemistry (IHC) on 78 post-LT HCC tissues. In vitro assays (CCK-8, Transwell, Colony formation) assessed MMP1/SPP1 roles in HCC cell proliferation and migration. Nine TRGs were prognostic in HCC, with MMP1 and SPP1 emerging as core regulators linked to EMT. Both genes were significantly upregulated in recurrent HCC tissues (1-year recurrence group vs. non-recurrence, P < 0.05) and correlated with reduced overall survival (OS) and recurrence-free survival (RFS). GSEA revealed EMT as a key enriched pathway. PPI network analysis highlighted MMP1/SPP1 centrality in ECM remodeling and cell adhesion. Clinical samples confirmed MMP1 association with vascular invasion (P = 0.023) and poor differentiation. In vitro, MMP1/SPP1 overexpression enhanced HCC cell proliferation, migration, and colony formation. Multivariate analysis identified MMP1 expression and tumor differentiation as independent recurrence risk factors. MMP1 and SPP1 are potential biomarkers for predicting post-LT HCC recurrence, likely driving metastasis via EMT activation. Their overexpression correlates with aggressive tumor behavior and adverse outcomes, offering prognostic utility and therapeutic targets to improve transplant outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.